Archive

May 7, 2025

Browsing

Trump’s latest Hollywood “hit” isn’t the kind you stream.

Threatening to slap a 100% tariff on films produced in foreign countries, the president’s announcement rattled several media stocks like Netflix, Inc. (NFLX), Walt Disney Co. (DIS), and others.

What makes the whole thing complicated is this:

  • No clear-cut definition of “foreign”: Many “American” films are shot abroad with foreign crews, locations, and studios.
  • Tax breaks abroad: Studios rely on international incentives to cut costs—think Marvel in the UK or Netflix in Korea (Squid Game).
  • Global revenues: Delivering content overseas boosts subscriptions.
  • Disruption to current projects: In-progress shoots and cross-border production deals could face sudden delays, cancellations, or financial penalties.
  • And last but not least, retaliation risk. Countries may hit back with tariffs or restrictions on U.S. films, hurting global revenues.

The result? A policy that aims to protect American film could end up undercutting it from every angle.

Which Media Stocks Are Still Worth Holding?

With Trump’s proposed 100% tariff and the looming threat of retaliation, you’re probably wondering: Which media stocks are still investable—and which ones are caught in the crossfire?

Let’s focus on the platforms that most Americans stream at home.

  • Netflix (NFLX) is the most exposed to Trump’s tariffs due to its heavy investment in international productions.
  • Disney (DIS) is most vulnerable both ways—to the U.S. tariff and international retaliation—in that over 60% of its box office revenue is international; plus, it operates theme parks in China, Hong Kong, Japan, and Europe.
  • Roku (ROKU) appears to be the least exposed, as it’s a content aggregator and not a producer. The bulk of its revenue comes from advertising, subscriptions, and platform fees, not from producing or exporting content.

NOTE: I’m excluding Amazon (AMZN) in favor of pure-play media entertainment stocks. While Amazon is not as exposed to foreign film tariffs, it’s exposed to the other tariffs.

First, how are these stocks performing relative to each other and the broader market (S&P 500)?

FIGURE 1. PERFCHARTS DISPLAYING THE RELATIVE PERFORMANCE OF ALL THREE STOCKS VS THE S&P. Netflix is far outpacing its two media peers.

Among these three, which stocks are currently the most investable—that is, which ones are showing favorable price action that could support a viable trading setup?

Netflix Technical Analysis: Uptrend Intact, But Caution Ahead

Let’s start with NFLX—the company most fundamentally exposed to the proposed tariffs on foreign-made films. Check out this daily chart.

FIGURE 2. DAILY CHART OF NFLX STOCK. No tariff fears are evident here as the stock continues its uptrend.

NFLX stock remains in a strong uptrend, with a StockCharts Technical Rank (SCTR) well above the 90-line, making it one of the top-performing large-cap stocks from a technical perspective. However, the Relative Strength Index (RSI) suggests the stock may be overbought, raising the possibility of a short-term pullback.

The  20-day Price Channel can help identify potential turning points since it highlights recent tops and bottoms. The green-shaded zone marks the first area of support, where a bounce may occur if the stock retreats in the coming sessions. If that level fails to hold, the red-shaded zone identifies a secondary support area aligned with the 200-day Simple Moving Average (SMA). A drop below this level without a strong rebound could signal a weakening of the current bullish trend.

Caution: Among the three stocks analyzed, Netflix appears to be most exposed to potential downside from Trump’s proposed tariffs on foreign-made films. Investors should remain cautious, as shifting geopolitical dynamics could alter the stock’s fundamental outlook and technical setup.

Now let’s take a look at Disney, a stock vulnerable to Trump’s proposed 100% tariffs on foreign-made films and the added threat of retaliatory tariffs from international markets.

Disney’s Recovery Potential Faces Global Headwinds

With a significant portion of its revenue coming from global box office sales and international theme parks, DIS stock is particularly sensitive to shifts in global trade policy. Take a look at this daily chart.

FIGURE 3. DAILY CHART OF DISNEY STOCK PRICE. Oof. Even if it recovers, will we see a breakout beyond the top range?

Disney is underperforming, and the key question is whether the stock is entering a potential recovery phase. The Full Stochastics Oscillator tends to mirror the stock’s cyclical movements well and suggests a possible short-term pullback.

If DIS holds above its most recent swing low support range (highlighted in red), the stock may attempt to retest the resistance area (highlighted in green), which aligns with the 200-day SMA and the most recent swing high.

One bullish signal to note: the Accumulation/Distribution Line (ADL) (shown in orange) is significantly above current price levels, suggesting that buying interest may be quietly building even while the stock trades near its lows. Is DIS a solid buy? Probably not at these levels. You will want to see a stronger indication (or confirmation) that DIS is recovering.

Also, note that DIS has been cycling the $80 to $125 range over the last three years. Unless you’re holding it as a dividend stock, there’s little indication yet that there’s going to be growth beyond this exceedingly wide range.

Is Roku Ready to Break Out, or Break Down?

Let’s analyze the daily chart of Roku.

FIGURE 4. DAILY CHART OF ROKU STOCK. It’s gearing for a breakout, but driven by what?

ROKU may be the least exposed to the proposed foreign film tariffs, but what’s going to drive it higher? Remember, the stock plunged in 2022–2024 due to falling ad revenue, widening losses, and a high-profile cybersecurity breach that shook investor confidence. Without a clear reason for a rebound, the stock may remain stuck.

The Chaikin Money Flow (CMF) is probably the most telling indicator here: buying and selling pressure are at a virtual standstill. There has to be a compelling catalyst to move the stock higher or lower. Still, ROKU appears to be rebounding from a technical standpoint, with overhead resistance levels at $71 and $82.

However, there needs to be something fundamental to validate this technical setup, especially if it turns bullish (like a break above resistance). So if for any reason you’re bullish on ROKU, monitor the fundamental side of this stock play. Right now, it doesn’t look very promising.

At the Close

Trump’s proposed tariff on foreign-made films has stirred up more than just Hollywood headlines; it’s forcing Wall Street to reassess risk across streaming and media stocks. Keep monitoring the technical, fundamental, and geopolitical factors. Don’t make any decisions until you see clear technical confirmation backed by a viable fundamental catalyst. And remember, geopolitical dynamics can still shift the conditions in an instant.


Disclaimer: This blog is for educational purposes only and should not be construed as financial advice. The ideas and strategies should never be used without first assessing your personal and financial situation, or without consulting a financial professional.

Triumph Gold (TSXV:TIG,OTC:TIGCF) is a Canadian gold exploration company well-positioned to benefit from a strengthening gold market. The company’s primary focus is advancing its 100 percent-owned Freegold Mountain Project, a district-scale property located in Yukon’s highly prospective Dawson Range gold-copper belt.

With defined multi-million ounce gold resources, significant potential for expansion, and promising discovery targets, Triumph Gold provides investors with exposure to a large, consolidated land package in one of Canada’s most mining-friendly jurisdictions.

The Freegold Mountain Project is Triumph Gold’s flagship asset — a district-scale property extending 34 kilometers along the highly mineralized Big Creek Fault system in Yukon. What sets this project apart is the widespread presence of mineralization across all major rock types on the property, including Paleozoic metamorphics, Jurassic intrusives, and Cretaceous intrusives. Each of these hosts distinct styles of precious and base metal mineralization, underscoring the project’s exceptional geological potential.

Company Highlights

  • Resource Base: Combined indicated resources of 1 million ounces and inferred resources of 1.08 million ounces gold equivalent across the Freegold Mountain project
  • Strategic Location: Positioned in the mineral-rich Dawson Range, home to major deposits including Newmont’s Coffee, Western Copper’s Casino, and Pembridge’s Minto mine
  • Multiple Deposit Types: Mineralization found in various forms (porphyry, epithermal, skarn) providing diversified exploration targets
  • Expansion Potential: All deposits remain open in multiple directions with numerous untested satellite targets
  • Fully Permitted: Exploration permits in place until 2025-2026 allowing for extensive drilling programs
  • Experienced Leadership: Management team with proven track records in mineral exploration, mine development and capital markets

This Triumph Gold profile is part of a paid investor education campaign.*

Click here to connect with Triumph Gold (TSXV:TIG) to receive an Investor Presentation

This post appeared first on investingnews.com

Joe Cavatoni, senior market strategist, Americas, at the World Gold Council, discusses the organization’s latest report on gold demand trends, highlight key data points from Q1.

He also shares his thoughts on gold’s record-setting rise, saying fundamentals remain strong.

Securities Disclosure: I, Charlotte McLeod, hold no direct investment interest in any company mentioned in this article.

This post appeared first on investingnews.com

The global pharmaceutical market reached a total value of US$1.38 trillion in 2024, according to Research and Markets, up significantly from the US$888 billion seen just over a decade earlier in 2010.

Experienced and novice investors alike may want to consider pharmaceutical exchange-traded funds (ETFs) as a way to gain exposure to the top pharma companies. Like all ETFs, pharmaceutical ETFs are a good option for those who want to trade a set of assets in the pharmaceutical industry instead of focusing solely on individual pharmaceutical stocks.

The main advantage of a pharmaceutical ETF is the fact that it can provide exposure to an overarching sector, but still trades like a stock. Pharma ETFs also offer less market volatility and lower fees and expenses.

Big pharma ETFs

Many of these funds have diverse holdings across some of the most important sectors in the pharmaceutical industry, including pain therapeutics, oncology, vaccines and biotechnology. Data was gathered on May 6, 2025.

1. VanEck Pharmaceutical ETF (NASDAQ:PPH)

Total assets under management: US$653.61 million

Established in late 2011, the VanEck Pharmaceutical ETF tracks the MVIS US Listed Pharmaceutical 25 Index. It has the capacity to provide big returns, even though there are some risks attached to the ETF. An analyst report indicates that investors looking for ‘tactical exposure’ to the pharma sector might consider this ETF as an investment option.

The ETF has 25 holdings, with the top five being Eli Lilly (NYSE:LLY) at a weight of 12.17 percent, AbbVie (NYSE:ABBV) at 6.48 percent, Johnson & Johnson (NYSE:JNJ) at 6.45 percent, Novartis (NYSE:NVS) at 5.43 percent and Cencora (NYSE:COR) at 5.34 percent.

2. iShares US Pharmaceuticals ETF (ARCA:IHE)

Total assets under management: US$571.51 million

Created on May 5, 2006, this iShares ETF tracks some of the top US pharma companies. In total, the iShares US Pharmaceuticals ETF has 41 holdings, with the vast majority being large-cap stocks.

Of its holdings, Eli Lilly and Johnson & Johnson are by far the largest portions in its portfolio, coming in at weightings of 24.55 percent and 23.38 percent, respectively. The next highest are Royalty Pharma (NASDAQ:RPRX) at 4.93 percent, Zoetis (NYSE:ZTS) at 4.80 percent and Viatris (NASDAQ:VTRS) at 4.57 percent.

3. Invesco Pharmaceuticals ETF (ARCA:PJP)

Total assets under management: US$240.1 million

The Invesco Pharmaceuticals ETF is primarily focused on providing exposure to US-based pharma companies. An analyst report states that this ETF chooses individual securities based on certain investment criteria, namely stock valuation and risk factors. Invesco changed the fund’s name from the Invesco Dynamic Pharmaceuticals ETF in August 2023.

This ETF was started on June 23, 2005, and currently tracks 31 companies. Its top holdings are Abbott Laboratories (NYSE:ABT) with a weight of 5.2 percent, AbbVie at 5.17 percent, Johnson & Johnson at 5 percent, Gilead Sciences (NASDAQ:GILD) at 4.94 percent and Eli Lilly at 4.86 percent.

4. SPDR S&P Pharmaceuticals ETF (ARCA:XPH)

Total assets under management: US$139.14 million

The SPDR S&P Pharmaceuticals ETF came into the market on June 19, 2006, and represents the pharmaceutical sub-industry sector of the S&P Total Markets Index. An analyst report for the ETF suggests that due to its narrow focus — which includes pharma giants that post ‘big returns’ during times of consolidation — it should not be considered for a long-term portfolio.

This pharma ETF tracks 43 holdings, with relatively close weighting among its holdings. XPH’s top five holdings are Corcept Therapeutics (NASDAQ:CORT) with a weight of 5.26 percent, Eli Lilly at 3.99 percent, Royalty Pharma (NASDAQ:RPRX) at 3.98 percent, Zoetis at 3.87 percent and Johnson & Johnson at 3.81 percent.

5. KraneShares MSCI All China Health Care Index ETF (ARCA:KURE)

Total assets under management: US$82.86 million

The KraneShares MSCI All China Health Care Index ETF was launched in February 2018 and tracks an index of large- and mid-cap Chinese stocks in the healthcare sector, all weighted by market capitalization. According to an analyst report, the fund provides investors with ‘exposure to a relatively small slice of the Chinese economy.’

The ETF tracks 46 holdings, and its top five are Jiangsu Hengrui Medicine (SHA:600276) at 8.33 percent, BeiGene (OTC Pink:BEIGF,HKEX:6160) at 7.88 percent, Shenzhen Mindray Bio-Medical Electronics (SZSE:300760) at 6.79 percent, Wuxi Biologics (OTC Pink:WXIBF,HKEX:2269) at 6.67 percent and Innovent Biologics (OTC Pink:IVBXF,HKEX:1801) at 5.51 percent .

Securities Disclosure: I, Melissa Pistilli, hold no investment interest in any of the companies mentioned in this article.

Keep reading…Show less
This post appeared first on investingnews.com

Copper prices are being pushed skyward as China’s stockpiles sit on the verge of depletion and as US demand for the red metal surges, fueled by looming trade restrictions under the Trump administration.

According to Mercuria, the market is undergoing “one of the greatest tightening shocks” in its history.

“At the current pace of draws, those Chinese inventories could deplete (to zero) by the middle of June,” Nicholas Snowdon, head of metals and mining research at the commodities trading house, told the Financial Times.

“Beijing had a razor-thin inventory buffer” to meet its soaring domestic demand, he added.

Copper inventories held in Chinese warehouses fell by a record 55,000 metric tons last week alone, sinking to just 116,800 metric tons. The sudden drawdown has placed further stress on a market that is already being strained by geopolitical tensions and a shift in long-term demand driven by clean energy initiatives and electrification.

The copper squeeze is being exacerbated by US buyers rushing to secure supply ahead of potential new tariffs.

US President Donald Trump has signaled that his administration is investigating “dumping and state-sponsored overproduction” of copper, echoing the rationale used for the imposition of 25 percent levies on steel and aluminum.

Copper futures prices on the Comex in New York have soared, rising 16.35 percent year-to-date to trade for US$4.69 per pound. The rally has been further buoyed by signs that China’s Ministry of Commerce is open to trade talks with the US — it has reportedly “taken note” of Washington’s signals and is evaluating the possibility of engagement.

As a result, inventories in Comex warehouses have surged to their highest levels since 2018.

The copper crunch is not confined to refined metal.

Analysts warn that Chinese access to copper scrap — a vital feedstock for its smelting industry — is also under threat from retaliatory trade measures and possible US export controls.

China relies heavily on imported scrap, and the US remains a key supplier. In 2024, the US exported 960,000 metric tons of copper scrap, nearly half of which went to China, according to data from Fastmarkets.

This year, exports are already trending lower: 142,000 metric tons were shipped in January and February, down from 149,000 metric tons in the same period last year. If the US imposes a ban on scrap exports or China imposes retaliatory import duties, the shortage in Asia’s largest economy could become even more acute.

Copper’s strategic role in the energy transition

Beyond short-term trade politics, copper is at the heart of a deeper structural transformation.

As the global economy pivots toward electrification and decarbonization, demand for the base metal is set to soar — despite advances in material efficiency and substitution.

During a recent webinar, Michael J. Finch, head of strategic initiatives at commodities price and data firm Benchmark Mineral Intelligence, noted that the accelerating deployment of electric vehicles (EVs), EV charging infrastructure and renewable energy sources is rapidly driving up copper intensity across energy systems.

“What … we can’t forget is, what are the requirements on the grid network? What are the requirements on power generation because of EVs, because of the charging infrastructure?” Finch said. He emphasized to attendees that while copper usage per EV has declined from around 100 kilograms in 2015 to about 68 to 70 kilograms today due to design optimizations and thrifting, total copper demand from the EV sector is still expected to rise sharply.

“We’re still looking at a market here … (of) over 5 million tonnes by 2040,” he said.

“That’s going to need a lot of charging infrastructure. That’s going to need a lot of grid upgrades. That’s going to need a lot of renewable power to be put in place,’ Finch added.

The overlapping dynamics of geopolitical uncertainty, rising protectionism and shifting energy priorities have created a volatile cocktail that could reshape global copper trade flows.

Efforts are underway in the US to take advantage of this shift. European copper producer Aurubis is investing 740 million euros in a new recycling facility in Richmond, Georgia, aimed at bolstering domestic supply. The plant, which is expected to be operational by the end of the fiscal year, will rely primarily on scrap sourced within the US.

Meanwhile, analysts are watching closely to see if the US and China can defuse trade tensions before they further destabilize a market that is already stretched thin.

Securities Disclosure: I, Giann Liguid, hold no direct investment interest in any company mentioned in this article.

Keep reading…Show less
This post appeared first on investingnews.com

Amazon’s Zoox issued a software recall for 270 of its robotaxis after a crash in Las Vegas last month, the company said Tuesday.

The recall surrounds a defect with the vehicle’s automated driving system that could cause it to inaccurately predict the movement of another car, increasing “the risk of a crash,” according to a report submitted to the National Highway Traffic Safety Administration.

Zoox submitted the recall after an April 8 incident in Las Vegas where an unoccupied Zoox robotaxi collided with a passenger vehicle, the NHTSA report states. There were no injuries in the crash and only minor damage occurred to both vehicles.

“After analysis and rigorous testing, Zoox identified the root cause,” the company said in a blog post. “We issued a software update that was implemented across all Zoox vehicles. All Zoox vehicles on the road today, including our purpose-built robotaxi and test fleet, have the updated software.”

Zoox paused all driverless vehicle operations while it reviewed the incident. It’s since resumed operations after rolling out the software update.

Amazon acquired Zoox in 2020 for over $1 billion, announcing at the time that the deal would help bring the self-driving technology company’s “vision for autonomous ride-hailing to reality.” However, Amazon has fallen far behind Alphabet’s Waymo, which has robotaxi services operating in multiple U.S. markets. Tesla has also announced plans to launch a robotaxi offering in Austin in June, though the company has missed many prior target dates for releasing its technology.

Zoox has been testing its robotaxis in Las Vegas, Nevada, and Foster City, California. Last month, Zoox began testing a small fleet of retrofitted vehicles in Los Angeles.

Last month, NHTSA closed a probe into two crashes involving Toyota Highlanders equipped with Zoox’s autonomous vehicle technology. The agency opened the probe last May after the vehicles braked suddenly and were rear-ended by motorcyclists, which led to minor injuries.

This post appeared first on NBC NEWS